Evidence map›Paper›PMID 30410396›Full record

ArticleCancer management and research2018

CAV3.1 knockdown suppresses cell proliferation, migration and invasion of prostate cancer cells by inhibiting AKT.

Shanbiao Hu, Ling Li, Wei Huang, Jie Liu, Gongbin Lan, Shaojie Yu, Longkai Peng, Xubiao Xie, Luoyan Yang, Yeqi Nian and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cancer management and research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Pro-tumoral CaScientific reports · 2026
    Article
  3. The Functional Interplay among GAD2, GABRG2, and CACNA1G Genes in Cancers.Asian Pacific journal of cancer prevention : APJCP · 2025
    Review
  4. Review
  5. Blockade of CaBritish journal of pharmacology · 2024
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Roles of calcium signaling in cancer metastasis to bone.Exploration of targeted anti-tumor therapy · 2022
    Review
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Shanbiao HuDepartment of Urological Organ Transplantation, The Second Xiangya Hospital of Central South University, Changsha, China.
Ling LiDepartment of Urology, The Second Xiangya Hospital of Central South University, Changsha, China, nianyeqi0314@csu.edu.cn; wangyinhuai@csu.edu.cn.
Wei HuangResearch Center of Carcinogenesis and Targeted Therapy, Xiangya Hospital, Central South University, Changsha, China.
Jie LiuDepartment of Pathology, Changsha Central Hospital, Changsha, China.
Gongbin LanDepartment of Urological Organ Transplantation, The Second Xiangya Hospital of Central South University, Changsha, China.
Shaojie YuDepartment of Urological Organ Transplantation, The Second Xiangya Hospital of Central South University, Changsha, China.
Longkai PengDepartment of Urological Organ Transplantation, The Second Xiangya Hospital of Central South University, Changsha, China.
Xubiao XieDepartment of Urological Organ Transplantation, The Second Xiangya Hospital of Central South University, Changsha, China.
Luoyan YangDepartment of Urology, The Second Xiangya Hospital of Central South University, Changsha, China, nianyeqi0314@csu.edu.cn; wangyinhuai@csu.edu.cn.
Yeqi NianDepartment of Urology, The Second Xiangya Hospital of Central South University, Changsha, China, nianyeqi0314@csu.edu.cn; wangyinhuai@csu.edu.cn.
Yinhuai WangDepartment of Urology, The Second Xiangya Hospital of Central South University, Changsha, China, nianyeqi0314@csu.edu.cn; wangyinhuai@csu.edu.cn.
Central South University · CNChangsha Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAberrant expression of CAV3.1, one of T-type Ca MATERIALS AND

methodsThe expression pattern of CAV3.1 was analyzed in multiple ways, including online analysis in Oncomine database, experimental analyses in cell lines, and collected clinical specimens using immunohistochemistry, quantitative reverse transcription polymerase chain reaction, and Western blot. Then, CAV3.1 was downregulated in PCa cells to explore its functions.

resultsUpregulated CAV3.1 in PCa tissues and cells was confirmed by analyzing mRNA expression datasets from Oncomine and quantitative reverse transcription polymerase chain reaction detection, respectively. Accordingly, significantly higher CAV3.1 protein level in PCa tissues specimens than that in benign prostatic hyperplasia tissues was indicated by immunohistochemical staining. In addition, CAV3.1 upregulation was positively associated with metastasis. Depletion of CAV3.1 impaired the proliferation, migration, and invasion ability of PCa cells demonstrating by cell functional experiments, such as CCK-8, cell cycle distribution, plate clone formation, scratch wound healing, and transwell invasion assays. Mechanistically, due to constrained Akt activity, CAV3.1 knockdown resulted in decreased level of CCND1, N-cadherin, and Vimentin, and increased level of E-cadherin whose expressions could be reversed by ectopic Akt expression. Similarly, ectopic Akt expression also rescued the inhibitory effects of CAV3.1 knockdown on cell functions like proliferation and migration in PCa cells.

conclusionUpregulated CAV3.1 is positively associated with the development of PCa. CAV3.1 knockdown can inhibit PCa cell proliferation, migration, and invasion by suppressing AKT activity.

Indexed as

AKT signalingCAV3.1invasionPCaproliferation

Identifiers

PMID30410396
PMCPMC6197829
OpenAlexW2896715673

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.